secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0000950170-24-112729
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics updates pipeline timelines: CORAL at 50% enrolled, SSRE in Dec, RIVER topline Q1 2025
--------------------------------------------------------------------------------

- Phase 2b CORAL trial for chronic cough in IPF enrolled 50% of target (N=160); SSRE expected December 2024.
- SSRE may maintain current size, upsize within pre-specified range, or evaluate for futility; topline H1 2025 if unchanged.
- Human Abuse Potential study completed dosing; topline results expected December 2024.
- Phase 2a RIVER trial for refractory chronic cough enrolled planned sample size; topline results now expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024112729/0000950170-24-112729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017024112729/trvi-20241003.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-112729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer